SEC Form 4 · accession 0001104659-19-011530
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Michael Gottesdiener
Officer — CEO and President · Director
Period of report
Feb 26, 2019
Accepted (ET)
Feb 28, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 26, 2019 | S | 635 | $30.13 | D | 527,431 | D | |
| Common StockF4 | Feb 27, 2019 | S | 1,814 | $30.01 | D | 525,617 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 26, 2019, Mr. Gottesdiener sold 635 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $30.01 to $30.14, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3On February 27, 2019, Mr. Gottesdiener sold 1,814 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F4This transaction was executed in multiple trades at prices ranging from $30.00 to $30.09, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.